Issue navigation
Volume 25, Issue Supplement_1, June 2023
Abstracts from the 2023 Pediatric Neuro-Oncology Research Conference
FINAL CATEGORY: ATRT/EMBRYONAL/ETMR - ATRT
ATRT-01. PARP INHIBITION AS A THERAPEUTIC TARGET IN ATRT
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i1, https://doi.org/10.1093/neuonc/noad073.001
ATRT-02. AN INFANTILE PINEAL EMBRYONAL TUMOR SHOWING PATHOLOGICAL FEATURES OF A CNS GANGLIONEUROBLASTOMA IN ADDITION TO SMARCA4 MUTATIONS AND THE METHYLATION PROFILING OF AN ATYPICAL TERATOID/RHABDOID TUMOR
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i1, https://doi.org/10.1093/neuonc/noad073.002
ATRT-03. THE ORAL IRON-MIMETIC GALLIUM MALTOLATE INHIBITS ATRT IN VIVO – IMAGING AND HISTOLOGICAL CHARACTERIZATION
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i1, https://doi.org/10.1093/neuonc/noad073.003
ATRT-04. TARGETING THE COREST COMPLEX HELPS REPROGRAM AT/RT’S ABNORMAL EPIGENETIC LANDSCAPE TOWARD A DIFFERENTIATION PHENOTYPE
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i1–i2, https://doi.org/10.1093/neuonc/noad073.004
ATRT-05. DNA DAMAGE REPAIR INHIBITOR LP-184 INHIBITS CELL GROWTH IN ATRT
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i2, https://doi.org/10.1093/neuonc/noad073.005
ATRT-06. ETMR TUMORIGENESIS MIRRORS RADIAL GLIAL DEVELOPMENT
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i2, https://doi.org/10.1093/neuonc/noad073.006
ATRT-07. CLINICAL APPLICABILITY OF C19MC MIRNA DETECTION IN LIQUID BIOPSIES OF ETMR PATIENTS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i2, https://doi.org/10.1093/neuonc/noad073.007
ATRT-08. THE SINGLE-CELL LANDSCAPE OF PINEOBLASTOMA IDENTIFIES DEVELOPMENTAL ORIGINS AND EXPOSES TUMORIGENIC DEPENDENCIES
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i2, https://doi.org/10.1093/neuonc/noad073.008
ATRT-09. COMBINATION OF THE PI3K INHIBITOR PAXALISIB WITH THE NUCLEOSIDE ANALOG GEMCITABINE ACTIVATES THE INTEGRATED STRESS RESPONSE AND EXTENDS SURVIVAL IN ORTHOTOPIC MODELS OF ATYPICAL TERATOID/RHABDOID TUMORS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i2–i3, https://doi.org/10.1093/neuonc/noad073.009
ATRT-10. SINGLE-CELL TRANSCRIPTOME ANALYSIS REVEALS CELLULAR HIERARCHIES AND THERAPEUTIC VULNERABILITIES OF ETMR
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i3, https://doi.org/10.1093/neuonc/noad073.010
ATRT-11. DEVELOPMENT OF NOVEL PRECLINICAL MODELS AND THERAPEUTIC STRATEGIES FOR ETMR
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i3, https://doi.org/10.1093/neuonc/noad073.011
ATRT-12. HYPERACTIVATING THE INTEGRATED STRESS RESPONSE WITH PROTEASOME INHIBITION IN AT/RT
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i3–i4, https://doi.org/10.1093/neuonc/noad073.012
ATRT-13. ASSESSMENT OF MITOCHONDRIAL BIOENERGETICS AND FISSION-FUSION DYNAMICS IN ETMR
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i4, https://doi.org/10.1093/neuonc/noad073.013
ATRT-14. ASSESSMENT OF MITOCHONDRIAL BIOENERGETICS AND FISSION-FUSION DYNAMICS IN ETMR
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i4, https://doi.org/10.1093/neuonc/noad073.014
ATRT-15. ATRTS HIJACK EPIGENETIC MECHANISMS TO PROMOTE IMMUNOSUPPRESSION AND ESCAPE FROM NK CELL THERAPY
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i4, https://doi.org/10.1093/neuonc/noad073.015
ATRT-16. THE PI3K INHIBITOR PAXALISIB COMBINES SYNERGISTICALLY WITH THE MEK INHIBITOR MIRDAMETINIB TO TARGET ATYPICAL TERATOID/RHABDOID TUMORS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i4–i5, https://doi.org/10.1093/neuonc/noad073.016
ATRT-17. CAR T CELL THERAPY TARGETING CLAUDIN-6 IS EFFECTIVE IN CELLULAR AND XENOGRAFT MODELS OF ATYPICAL TERATOID/RHABDOID TUMOR
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i5, https://doi.org/10.1093/neuonc/noad073.017
ATRT-18. ELUCIDATING THE ETMR MICROENVIRONMENT USING SPATIAL MULTI-OMICS TECHNOLOGIES
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i5, https://doi.org/10.1093/neuonc/noad073.018
ATRT-19. RARE EMBRYONAL TUMORS INCLUDING EMBRYONAL TUMOR MULTILAYER ROSETTE, OUTCOME AND PATTERN OF TREATMENT FAILURE: MD ANDERSON CANCER CENTER EXPERIENCE
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i5, https://doi.org/10.1093/neuonc/noad073.019
FINAL CATEGORY: BASIC BIOLOGY/STEM CELLS/MODELS - BIOL
BIOL-01. GENERATION AND MULTI-OMICS CHARACTERIZATION OF 203 PEDIATRIC CNS TUMOUR MODELS REVEALS NEW THERAPEUTIC VULNERABILITIES
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i5–i6, https://doi.org/10.1093/neuonc/noad073.020
BIOL-02. MODELING BRAIN TUMORS IN VIVO AND WITH HUMAN ORGANOIDS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i6, https://doi.org/10.1093/neuonc/noad073.021
BIOL-03. NOVEL GENETICALLY ENGINEERED MOUSE MODEL FOR CHOROID PLEXUS CARCINOMA MIMICS HUMAN DISEASE
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i6, https://doi.org/10.1093/neuonc/noad073.022
BIOL-04. FROM MSWI/SNF’S ROLES IN PROTEIN SYNTHESIS TO NEW THERAPEUTIC OPPORTUNITIES
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i6, https://doi.org/10.1093/neuonc/noad073.023
BIOL-05. IDENTIFICATION AND VALIDATION OF PA2G4 AS A POTENTIAL THERAPEUTIC TARGET IN PEDIATRIC DIFFUSE GLIOMAS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i6, https://doi.org/10.1093/neuonc/noad073.024
BIOL-06. UNDERSTANDING OLIGODENDROCYTE PROGENITOR CELL CONTRIBUTION TO GLIOMAGENESIS USING A NOVEL PHARMACOGENETIC ABLATION TOOL
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i6–i7, https://doi.org/10.1093/neuonc/noad073.025
BIOL-07. DISTINCTIVE FEATURES OF HIGH-GRADE GLIOMA MOUSE MODELS REVEALED BY SINGLE-NUCLEUS RNA-SEQUENCING GUIDE PRE-CLINICAL MODEL SELECTION
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i7, https://doi.org/10.1093/neuonc/noad073.026
BIOL-08. RADIATION DRIVES METASTASIS IN MEDULLOBLASTOMA THROUGH AN INFLAMMATORY PROCESS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i7, https://doi.org/10.1093/neuonc/noad073.027
BIOL-09. PROTEOMIC ANALYSES REVEAL THAT CO-CULTURE OF DIFFUSE INTRINSIC PONTINE GLIOME (DIPG) WITH CORTICAL ORGANOIDS ALTERS CELL ADHESION, DNA SYNTHESIS AND REPLICATION, AND DENDRITIC GROWTH SIGNALLING
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i7, https://doi.org/10.1093/neuonc/noad073.028
BIOL-10. MOUSE MODELING OF PEDIATRIC MYCN GLIOMA REVEALS INTRATUMORAL HETEROGENEITY INCLUDING NEURONAL AND OLIGODENDROGLIAL LINEAGE SIGNATURES
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i7–i8, https://doi.org/10.1093/neuonc/noad073.029
BIOL-11. PRECLINICAL MODELLING OF PEDIATRIC BRAIN TUMORS USING ORGANOID TECHNOLOGY
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i8, https://doi.org/10.1093/neuonc/noad073.030
BIOL-12. ENHANCING IMMUNE-MEDIATED TUMOR CONTROL IN MURINE MODELS OF GROUP 3 MEDULLOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i8, https://doi.org/10.1093/neuonc/noad073.031
BIOL-13. DEPLOYING NEW MODELS OF NF-1 MUTANT LOW GRADE GLIOMA TO ACCELERATE THERAPEUTIC DEVELOPMENT
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i8, https://doi.org/10.1093/neuonc/noad073.032
BIOL-14. FROM NON-MALIGNANT TO MALIGNANT: GENERATING AND TARGETING DIFFUSE MIDLINE GLIOMA IN A NOVEL HUMAN PONTINE ORGANOID MODEL
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i8–i9, https://doi.org/10.1093/neuonc/noad073.033
BIOL-15. PATIENT-DERIVED XENOGRAFTS OF MATCHED PRIMARY-RECURRENT PEDIATRIC BRAIN TUMORS AS A RESOURCE FOR IDENTIFYING THERAPY RESISTANCE PROFILES
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i9, https://doi.org/10.1093/neuonc/noad073.034
BIOL-16. OBESOGENIC DIET EXPOSURE INCREASES NF1-OPTIC PATHWAY GLIOMA FORMATION IN PART THROUGH EFFECTS ON THE CELL OF ORIGIN
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i9, https://doi.org/10.1093/neuonc/noad073.035
BIOL-17. DISSECTING THE EXPRESSION AND FUNCTION OF ANGIOPOIETIN-1 IN PEDIATRIC BRAIN TUMORS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i9, https://doi.org/10.1093/neuonc/noad073.036
BIOL-18. NEWLY DEVELOPED REPLICATION REPAIR DEFICIENT (RRD) MOUSE MODELS PROVIDE INSIGHTS INTO MEDULLOBLASTOMA/GLIOMAGENESIS AND RESPONSE TO IMMUNOTHERAPY
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i9–i10, https://doi.org/10.1093/neuonc/noad073.037
BIOL-19. DIFFUSE MIDLINE GLIOMA CEREBRAL ORGANOID MODEL AND MULTIOMICS CHARACTERIZATION
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i10, https://doi.org/10.1093/neuonc/noad073.038
BIOL-20. BIOPROCESSING OF SURGICAL PEDIATRIC BRAIN TUMOR SPECIMENS FOR GENOME-GUIDED PERSONALIZED DRUG TESTING
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i10, https://doi.org/10.1093/neuonc/noad073.039
BIOL-21. PATIENT-DERIVED, THREE-DIMENSIONAL ORGANOID PLATFORM FOR PEDIATRIC BRAIN TUMOR MODELING AND THERAPEUTIC TESTING
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i10, https://doi.org/10.1093/neuonc/noad073.040
BIOL-22. CHILDREN’S BRAIN TUMOR NETWORK PRECLINICAL TUMOR MODELS DEVELOPMENT AND SHARING PLATFORM: COLLABORATIVE MODEL EMPOWERING PEDIATRIC BRAIN TUMOR DISCOVERY AND GLOBAL RESEARCH
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i10–i11, https://doi.org/10.1093/neuonc/noad073.041
BIOL-23. LOSS OF MICRORNAS COOPERATES WITH TUMOR SUPPRESSORS TO INITIATE MYC-DEPENDENT METASTATIC MEDULLOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i11, https://doi.org/10.1093/neuonc/noad073.042
BIOL-24. USING NEEDLE WASH SPECIMEN AFTER STEREOTACTIC BIOPSY TO DEVELOP PDOX MODELS OF DIPG AND DIFFUSE MIDLINE GLIOMAS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i11, https://doi.org/10.1093/neuonc/noad073.043
FINAL CATEGORY: CANCER NEUROSCIENCE - CNSC
CNSC-01. GABAERGIC NEURON-TO-GLIOMA SYNAPSES IN DIFFUSE MIDLINE GLIOMAS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i11, https://doi.org/10.1093/neuonc/noad073.044
CNSC-02. INVESTIGATING THE ROLE OF THE WNT SIGNALING TRANSDUCTION PATHWAY IN GLIOMA BLOOD-BRAIN-BARRIER INTEGRITY
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i11–i12, https://doi.org/10.1093/neuonc/noad073.045
CNSC-03. EXPLORING STRUCTURAL DISRUPTION OF TRICELLULAR JUNCTIONS TO ENHANCE BLOOD-BRAIN-BARRIER PERMEABILITY
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i12, https://doi.org/10.1093/neuonc/noad073.046
CNSC-04. EVALUATING LONGITUDINAL WORKING MEMORY PERFORMANCE IN PEDIATRIC PATIENTS WITH CRANIOPHARYNGIOMA VIA FMRI
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i12, https://doi.org/10.1093/neuonc/noad073.047
FINAL CATEGORY: DIFFUSE INTRINSIC PONTINE GLIOMA/DIFFUSE MIDLINE GLIOMAS - DPIG
DIPG-01. LIN28B EXPRESSION IN DIFFUSE MIDLINE GLIOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i12, https://doi.org/10.1093/neuonc/noad073.048
DIPG-02. A NOVEL STRATEGY TO RADIOSENSITISE DIFFUSE MIDLINE GLIOMAS VIA DUAL-TARGETING OF GLUCOSE METABOLISM
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i12–i13, https://doi.org/10.1093/neuonc/noad073.049
DIPG-03. IDENTIFICATION OF NEW THERAPEUTIC TARGETS BY ARRAYED CRISPRA-BASED APPROACH TO MAP RADIORESISTANCE IN DMG
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i13, https://doi.org/10.1093/neuonc/noad073.050
DIPG-04. TUMOR CELL-INTRINSIC TIM-3 PROMOTES DIFFUSE INTRINSIC PONTINE GLIOMA TUMORIGENESIS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i13, https://doi.org/10.1093/neuonc/noad073.051
DIPG-05. EVALUATION OF TELOMERE-MODIFYING COMPOUND THIO AS A RADIOSENSITIZER AND IMMUNOMODULATOR TO TREAT DIPG
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i13, https://doi.org/10.1093/neuonc/noad073.052
DIPG-06. PRECLINICAL EVALUATION OF A NOVEL ACVR1 INHIBITOR IN DIFFUSE INTRINSIC PONTINE GLIOMAS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i13–i14, https://doi.org/10.1093/neuonc/noad073.053
DIPG-07. ROBUST CGAS-STING PATHWAY MEDIATED-INDUCTION OF ANTITUMOR ADAPTIVE IMMUNE RESPONSE: A POTENTIAL FOR DMG IMMUNOTHERAPY
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i14, https://doi.org/10.1093/neuonc/noad073.054
DIPG-08. THE LANDSCAPE OF TUMOR CELL STATES AND SPATIAL ORGANIZATION IN H3-K27M MUTANT DIFFUSE MIDLINE GLIOMA ACROSS AGE AND LOCATION
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i14, https://doi.org/10.1093/neuonc/noad073.055
DIPG-09. ATOVAQUONE RADIOSENSITISES DIFFUSE MIDLINE GLIOMAS BY INHIBITING MITOCHONDRIAL METABOLISM AND HYPOXIA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i14, https://doi.org/10.1093/neuonc/noad073.056
DIPG-10. DELTA-24-RGDOX PROMOTES ANTITUMOR IMMUNE RESPONSE IN DMG MODELS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i14–i15, https://doi.org/10.1093/neuonc/noad073.057
DIPG-11. DISSECTING THE DIFFUSE MIDLINE GLIOMA TUMOR MICROENVIRONMENT COMMUNICATIONS USING MULTI-OMICS APPROACHES
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i15, https://doi.org/10.1093/neuonc/noad073.058
DIPG-12. OUTCOMES IN PEDIATRIC MALIGNANT CENTRAL NERVOUS SYSTEM TUMORS UTILIZING TEMOZOLOMIDE, BEVACIZUMAB, AND IRINOTECAN
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i15, https://doi.org/10.1093/neuonc/noad073.059
DIPG-13. NEW IMMUNOCOMPETENT GENETICALLY-ENGINEERED MOUSE MODELS OF PEDIATRIC-TYPE DIFFUSE HIGH-GRADE GLIOMAS REVEAL MECHANISMS OF TUMOR INITIATION AND PROGRESSION
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i15, https://doi.org/10.1093/neuonc/noad073.060
DIPG-14. PROTEOGENOMICS PROFILING REVEALS ENRICHED NON-HISTONE PROTEIN METHYLTRANSFERASES AS NEW THERAPEUTIC TARGETS IN DIPG
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i15–i16, https://doi.org/10.1093/neuonc/noad073.061
DIPG-15. CONCURRENT GB-13 (IL13.E13K-PE4E) IMPROVES THE EFFICACY OF RADIATION THERAPY IN DIFFUSE INTRINSIC PONTINE GLIOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i16, https://doi.org/10.1093/neuonc/noad073.062
DIPG-16. ACUTE VERSUS PROLONGED CONVECTION-ENHANCED DELIVERY OF ALISERTIB INTO H3 K27M-MUTANT MODELS OF DIFFUSE MIDLINE GLIOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i16, https://doi.org/10.1093/neuonc/noad073.063
DIPG-17. TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA USING ALLELE-SPECIFIC SIRNA TARGETING H3.3 K27M MUTANT HISTONE
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i16, https://doi.org/10.1093/neuonc/noad073.064
DIPG-18. AI HUNTING FOR NEW DRUGS IN PEDIATRIC GLIOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i16, https://doi.org/10.1093/neuonc/noad073.065
DIPG-19. BAF COMPLEX PERTURBATION AS A NOVEL THERAPEUTIC OPPORTUNITY IN H3K27M PEDIATRIC GLIOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i16–i17, https://doi.org/10.1093/neuonc/noad073.066
DIPG-20. DELINEATING MEDIATORS OF ONCOGENESIS IN FOXR2-EXPRESSING DIFFUSE MIDLINE GLIOMAS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i17, https://doi.org/10.1093/neuonc/noad073.067
DIPG-21. LINKING DETERMINATION OF CELL FATE IN THE DEVELOPING CENTRAL NERVOUS SYSTEM TO DIFFUSE MIDLINE GLIOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i17, https://doi.org/10.1093/neuonc/noad073.068
DIPG-22. TRIPTOLIDE AS A POTENTIALLY PROMISING THERAPY FOR DIFFUSE MIDLINE GLIOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i17, https://doi.org/10.1093/neuonc/noad073.069
DIPG-23. THE ROLE OF FOXO3 IN DMG RESISTANCE AND RESPONSE TO THERAPIES TARGETING DMG METABOLISM
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i17–i18, https://doi.org/10.1093/neuonc/noad073.070
DIPG-24. BRD4 INHIBITION AS A RADIOSENSITIZER THROUGH BLOCKING DNA REPAIR FOR THE TREATMENT OF DIFFUSE MIDLINE GLIOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i18, https://doi.org/10.1093/neuonc/noad073.071
DIPG-25. MAPPING TUMOR MICROENVIRONMENT USING EMERGING TECHNOLOGIES FOR PEDIATRIC BRAIN CANCERS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i18, https://doi.org/10.1093/neuonc/noad073.072
DIPG-26. CLINICAL AND GENOMIC ANALYSIS OF H3K27M-DMG LONG-TERM SURVIVORS REVEALS ENRICHMENT IN MAPK PATHWAY ALTERATIONS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i18–i19, https://doi.org/10.1093/neuonc/noad073.073
DIPG-27. DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) CHALLENGE: FROM GENE EXPRESSION PROFILE TO DRUG
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i19, https://doi.org/10.1093/neuonc/noad073.074
DIPG-28. IDENTIFICATION AND TARGETING OF METABOLIC VULNERABILITIES IN COMBINATION WITH PDGFRA-INHIBITION IN DIFFUSE MIDLINE GLIOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i19, https://doi.org/10.1093/neuonc/noad073.075
DIPG-29. A CONNECT CONSORTIUM PRECLINICAL STUDY IDENTIFIES MEK INHIBITION AND RADIATION AS POTENTIAL COMBINATION PARTNERS FOR THE ALK2 INHIBITOR TP-0184 IN ACVR1-MUTANT DMG
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i19, https://doi.org/10.1093/neuonc/noad073.076
DIPG-30. HIF2 OVEREXPRESSION DICTATES AGGRESSIVENESS ADDITIONALLY TO TP53 MUTATIONS IN H3.3K27M PEDIATRIC HIGH-GRADE GLIOMAS THROUGH RAS-MAPK AND WNT/BCATENIN PATHWAYS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i19–i20, https://doi.org/10.1093/neuonc/noad073.077
DIPG-31. HIF-1A AND HIF-2A COMBINATORIAL TARGETING OR HOW TO REVERSE THEIR BALANCED ONCOGENIC IMPACT
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i20, https://doi.org/10.1093/neuonc/noad073.078
DIPG-32. PRECLINICAL TESTING OF THE EFFICACY AND SAFETY OF CRISPR/CAS9 GENE EDITED CAR-T CELL THERAPY FOR DIFFUSE MIDLINE GLIOMA (DMG)
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i20, https://doi.org/10.1093/neuonc/noad073.079
DIPG-33. P16 IMMUNOHISTOCHEMICAL EXPRESSION AS A SURROGATE ASSESSMENT OF CDKN2A ALTERATION IN GLIOMAS LEADING TO PROGNOSTIC SIGNIFICANCES
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i20, https://doi.org/10.1093/neuonc/noad073.080
DIPG-34. IMMUNE SYNAPSE OPTIMIZED GRP78-SPECIFIC CAR T CELLS ELICIT AN IMPROVED ANTITUMOR RESPONSE AGAINST DIPGS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i20, https://doi.org/10.1093/neuonc/noad073.081
DIPG-35. IDENTIFYING DRIVER-SPECIFIC VULNERABILITIES IN PAEDIATRIC HIGH GRADE GLIOMA SUBTYPES
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i20–i21, https://doi.org/10.1093/neuonc/noad073.082
DIPG-36. H3K27M HISTONE MUTANT GLIOMAS ARE SENSITIVE TO METHIONINE LOSS AND MAT2A INHIBITION THROUGH A NOVEL FEEDBACK MECHANISM BETWEEN AMD1 AND METTL16
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i21, https://doi.org/10.1093/neuonc/noad073.083
DIPG-37. TRANSCRIPTIONAL, EPIGENETIC, AND IMMUNOLOGICAL FEATURES OF PAEDIATRIC-TYPE H3 K27-ALTERED DIFFUSE MIDLINE GLIOMAS ORIGINATING FROM DIFFERENT BRAIN LOCATIONS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i21, https://doi.org/10.1093/neuonc/noad073.084
DIPG-38. PATIENT-DERIVED THREE-DIMENSIONAL AVATARS REVEAL CELL-AUTONOMOUS MECHANISMS DRIVING INVASION AND METASTATIC PROGRESSION IN DIFFUSE MIDLINE GLIOMAS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i21–i22, https://doi.org/10.1093/neuonc/noad073.085
DIPG-39. SIGNALING NETWORKS IN PEDIATRIC-TYPE DIFFUSE HIGH GRADE GLIOMAS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i22, https://doi.org/10.1093/neuonc/noad073.086
DIPG-40. HYPOXIC STRESS EXPOSES EPIGENETIC TARGETS TO ENHANCE RADIOTHERAPY RESPONSE IN H3K27M-POSITIVE PEDIATRIC DIFFUSE MIDLINE GLIOMAS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i22, https://doi.org/10.1093/neuonc/noad073.087
DIPG-41. EXPLORING BRAIN PENETRANT PEPTIDE-DRUG CONJUGATES IN DIFFUSE INTRINSIC PONTINE GLIOMA MODELS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i22, https://doi.org/10.1093/neuonc/noad073.088
DIPG-42. MAPPING THE DNA METHYLATION LANDSCAPE OF DIPG REVEALS NOTABLE METHYLOME VARIABILITY RESPONSIVE TO PHARMACOLOGIC MODULATION
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i22, https://doi.org/10.1093/neuonc/noad073.089
DIPG-43. CLINICAL AND MOLECULAR CHARACTERISTIC OF A NEW SUBTYPE OF DMG, H3K27-ALTERED WITH MAPK-ACTIVATING CO-DRIVER MUTATIONS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i22–i23, https://doi.org/10.1093/neuonc/noad073.090
DIPG-44. DIFFUSE MIDLINE GLIOMA WITH EXTRACRANIAL METASTASIS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i23, https://doi.org/10.1093/neuonc/noad073.091
DIPG-45. ELONGIN B REGULATES H3K27M CHROMATIN INCORPORATION TO PROMOTE MALIGNANCY IN DIFFUSE MIDLINE GLIOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i23, https://doi.org/10.1093/neuonc/noad073.092
DIPG-46. TARGETING THE METABOLIC ERK5-PFKFB3 AXIS IN PEDIATRIC DIFFUSE MIDLINE GLIOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i23–i24, https://doi.org/10.1093/neuonc/noad073.093
DIPG-47. DISCOVERING A MOLECULAR BASIS FOR VULNERABILITY OF H3K27M-DMG TO HISTONE DEACETYLASE INHIBITORS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i24, https://doi.org/10.1093/neuonc/noad073.094
DIPG-48. DIPG THROUGH THE LOOKING GLASS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i24, https://doi.org/10.1093/neuonc/noad073.095
DIPG-49. A SYSTEMS BIOLOGY APPROACH TO DEFINING AND TARGETING CELL STATE-SPECIFIC MASTER REGULATOR DEPENDENCIES IN DIFFUSE MIDLINE GLIOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i24, https://doi.org/10.1093/neuonc/noad073.096
DIPG-50. INSIGHTS INTO TUMORIGENESIS OF DIFFUSE INTRINSIC PONTINE GLIOMA-ONCOHISTONE AND SIGNALING
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i24, https://doi.org/10.1093/neuonc/noad073.097
DIPG-51. ABDOMINAL METASTASES OF DIFFUSE MIDLINE GLIOMA, H3K27-ALTERED WITH A VENTRICULOPERITONEAL SHUNT
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i24–i25, https://doi.org/10.1093/neuonc/noad073.098
DIPG-52. EXTRAPONTINE PROGRESSION WITH STABLE PONTINE DISEASE POST-RADIOTHERAPY IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) ON A CONNECT TRIAL: IMPLICATIONS FOR RADIATION TREATMENT VOLUMES
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i25, https://doi.org/10.1093/neuonc/noad073.099
DIPG-53. LSD1 DEGRADATION SYNERGIZES WITH HDAC INHIBITION IN PEDIATRIC H3K27M DIFFUSE MIDLINE GLIOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i25, https://doi.org/10.1093/neuonc/noad073.100
DIPG-54. UPDATED FINDINGS FROM THE PHASE IB STUDY OF UNESBULIN (PTC596) IN CHILDREN WITH NEWLY-DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) AND HIGH-GRADE GLIOMA (HGG): A REPORT FROM THE COLLABORATIVE NETWORK FOR NEURO-ONCOLOGY CLINICAL TRIALS (CONNECT)
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i25–i26, https://doi.org/10.1093/neuonc/noad073.101
DIPG-55. DIRECT BRAIN-TO-BRAIN WORKFLOW ENABLES THE PRECLINICAL MODELING OF PEDIATRIC GLIOMAS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i26, https://doi.org/10.1093/neuonc/noad073.102
DIPG-56. PEDIATRIC GLIOMAS EXHIBIT A UNIQUE LIPID METABOLIC PHENOTYPE DISTINCT FROM ADULT GBMS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i26, https://doi.org/10.1093/neuonc/noad073.103
DIPG-57. TESTING FOR SYNERGY AMONG RADIATION AND HIGHLY CLINICALLY RELEVANT CHEMOTHERAPEUTIC AGENTS IN PATIENT-DERIVED MODELS OF DIFFUSE MIDLINE GLIOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i26, https://doi.org/10.1093/neuonc/noad073.104
FINAL CATEGORY: EPENDYMOMA - EPEN
EPEN-01. ZFTA-RELA FUSION PROGRAMS CONVERGE ON YAP PATHWAY ACTIVATION IN EPENDYMOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i26, https://doi.org/10.1093/neuonc/noad073.105
EPEN-02. OPTIMISING BIOMARKERS FOR ACCURATE EPENDYMOMA DIAGNOSIS, PROGNOSTICATION AND STRATIFICATION WITHIN INTERNATIONAL CLINICAL TRIALS: A BIOMECA STUDY
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i26–i27, https://doi.org/10.1093/neuonc/noad073.106
EPEN-03. ZFTA-RELA LOCALIZATION DYNAMICS REGULATE TRANSCRIPTIONAL CONTROL
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i27, https://doi.org/10.1093/neuonc/noad073.107
EPEN-04. DEVELOPMENT OF B7-H3-TARGETED CAR T CELL THERAPY FOR EPENDYMOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i27, https://doi.org/10.1093/neuonc/noad073.108
EPEN-05. TRANSCRIPTIONAL FACTOR-DIRECTED EPIGENETIC REGULATION IN CANCER NEUROSCIENCE OF ZFTA-RELA EPENDYMOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i27, https://doi.org/10.1093/neuonc/noad073.109
EPEN-06. CHARACTERISING THE DEVELOPMENTAL ORIGINS AND TRAJECTORIES OF ZFTA-RELA FUSION EPENDYMOMA IN A NOVEL MOUSE MODEL
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i27–i28, https://doi.org/10.1093/neuonc/noad073.110
EPEN-07. A MULTICENTER STUDY OF POOR PROGNOSIS CHROMOSOME 1Q GAIN AND/OR 6Q LOSS IN POSTERIOR FOSSA A EPENDYMOMA SHOWS INCREASED PREVALENCE FROM 20% AT DIAGNOSIS TO 60% AT FIRST RECURRENCE
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i28, https://doi.org/10.1093/neuonc/noad073.111
EPEN-08. COMBINED PDGFR INHIBITOR AXITINIB AND RETINOID TRETINOIN DECREASES PROLIFERATION AND HIGH-RISK NEOPLASTIC SUBPOPULATION PROPORTIONS PFA EPENDYMOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i28, https://doi.org/10.1093/neuonc/noad073.112
EPEN-09. UTILITY OF RADIATION THERAPY IN SPINAL CORD MYXOPAPILLARY EPENDYMOMAS: A REVIEW OF THE LITERATURE
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i28, https://doi.org/10.1093/neuonc/noad073.113
EPEN-10. SPINAL EPENDYMOMA WITH MYCN-AMPLIFICATION – A DISEASE OF CHILDHOOD AND YOUNG ADULTHOOD WITH DISMAL PROGNOSIS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i28–i29, https://doi.org/10.1093/neuonc/noad073.114
EPEN-11. CHARACTERIZATION OF THE SPATIAL ARCHITECTURE OF INTRATUMORAL CELL STATES IN PEDIATRIC HIGH-RISK EPENDYMOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i29, https://doi.org/10.1093/neuonc/noad073.115
EPEN-12. COMPARING CELLULAR HIERARCHIES AND SPATIAL ARCHITECTURE ACROSS MOLECULAR SUBGROUPS OF SUPRATENTORIAL EPENDYMOMAS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i29, https://doi.org/10.1093/neuonc/noad073.116
EPEN-13. PATTERN OF RELAPSE IN POSTERIOR FOSSA EPENDYMOMA GROUP A
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i29–i30, https://doi.org/10.1093/neuonc/noad073.117
FINAL CATEGORY: GENOMICS/EPIGENOMICS/METABOLOMICS - METB
METB-01. EXTRACHROMOSOMAL DNA IS ASSOCIATED WITH ONCOGENE AMPLIFICATION AND POOR SURVIVAL ACROSS MULTIPLE PEDIATRIC CANCER TYPES
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i30, https://doi.org/10.1093/neuonc/noad073.118
METB-02. DECIPHERING THE CELLULAR HETEROGENEITY OF INFANT-TYPE HEMISPHERIC GLIOMAS USING SINGLE-NUCLEI MULTI-OMICS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i30, https://doi.org/10.1093/neuonc/noad073.119
METB-03. THE DISTINCT GENOMICS OF HIGH-GRADE INFANT GLIOMAS AMONG PEDIATRIC GLIOMAS HARBORING RECEPTOR TYROSINE KINASE FUSIONS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i30, https://doi.org/10.1093/neuonc/noad073.120
METB-04. THE MOLECULAR CHARACTERIZATION INITIATIVE (MCI): A CLINICAL AND GENOMIC RESOURCE FOR THE PEDIATRIC BRAIN TUMOR COMMUNITY
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i30–i31, https://doi.org/10.1093/neuonc/noad073.121
METB-05. NON-INVASIVE DIAGNOSIS OF BRAINSTEM GLIOMAS IN PEDIATRIC, ADOLESCENT, AND YOUNG ADULT PATIENTS THROUGH CEREBROSPINAL FLUID CELL-FREE DNA SEQUENCING
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i31, https://doi.org/10.1093/neuonc/noad073.122
METB-06. HIGH FREQUENCY OF CLINICALLY RELEVANT ALTERATIONS DETECTED BY INTEGRATED TUMOR AND GERMLINE GENE PANEL TESTING IN CHILDREN WITH CNS TUMORS – RESULTS FROM THE TEXAS KIDSCANSEQ STUDY
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i31, https://doi.org/10.1093/neuonc/noad073.123
METB-07. MINIMALLY-INVASIVE DIAGNOSIS OF DIFFUSE LEPTOMENINGEAL GLIONEURONAL TUMOR (DLGNT) USING CEREBROSPINAL FLUID CELL-FREE DNA SEQUENCING IN PEDIATRIC AND YOUNG ADULT PATIENTS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i31, https://doi.org/10.1093/neuonc/noad073.124
METB-08. GENOMIC AND MOLECULAR PROFILING OF PEDIATRIC CENTRAL NERVOUS SYSTEM TUMORS: A SINGLE INSTITUTION ANALYSIS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i31–i32, https://doi.org/10.1093/neuonc/noad073.125
METB-09. GERMLINE PATHOGENIC VARIANTS IN 838 PEDIATRIC BRAIN TUMOR PATIENTS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i32, https://doi.org/10.1093/neuonc/noad073.126
METB-10. EXPLAINABLE ARTIFICIAL INTELLIGENCE REVEALS DNA METHYLATION PATTERNS UNDERLYING BRAIN TUMOR CLASSIFICATION
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i32, https://doi.org/10.1093/neuonc/noad073.127
METB-11. EXPANSION OF THE PEDIATRIC BRAIN TUMOR ATLAS: AN OPEN SCIENCE EFFORT OF CHILDREN’S BRAIN TUMOR NETWORK, KIDS FIRST DATA RESOURCE AND CHILDHOOD CANCER DATA INITIATIVE
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i32, https://doi.org/10.1093/neuonc/noad073.128
METB-12. CLINICAL MONITORING OF MEASURABLE RESIDUAL DISEASE BY CELL-FREE DNA IN PEDIATRIC BRAIN TUMORS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i32–i33, https://doi.org/10.1093/neuonc/noad073.129
METB-13. A SINGLE-CELL GENETIC IN VIVO LINEAGE-TRACING PLATFORM FOR MEDULLOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i33, https://doi.org/10.1093/neuonc/noad073.130
FINAL CATEGORY: GERM CELL TUMORS/RARE TUMORS - RARE
RARE-02. OBSERVATIONAL REGISTRY STUDY OF TREATMENT PRACTICES AND LONG-TERM OUTCOMES OF CHILDREN WITH NEUROFIBROMATOSIS TYPE 1 (NF1) AND PLEXIFORM NEUROFIBROMAS (PN) INITIATING SELUMETINIB IN REAL-WORLD PRACTICE IN THE UNITED STATES (US): STUDY DESIGN AND METHODOLOGY
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i33, https://doi.org/10.1093/neuonc/noad073.131
RARE-03. GENOME-WIDE ASSOCIATION STUDY OF INTRACRANIAL GERM CELL TUMORS: A COMMON DELETION AT BAK1 ATTENUATES THE ENHANCER ACTIVITY AND CONFERS RISK FOR THE BRAIN TUMORS IN CHILDREN ADOLESCENTS AND YOUNG ADULTS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i33–i34, https://doi.org/10.1093/neuonc/noad073.132
RARE-04. DEVELOPMENT OF A PLATFORM TO PROFILE MICRORNA IN CEREBROSPINAL FLUID FROM PATIENTS WITH INTRACRANIAL GERM CELL TUMORS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i34, https://doi.org/10.1093/neuonc/noad073.133
RARE-05. MOLECULAR HETEROGENEITY OF PEDIATRIC CHOROID PLEXUS CARCINOMAS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i34, https://doi.org/10.1093/neuonc/noad073.134
RARE-06. DISSECTING CELLULAR DIFFERENTIATION HETEROGENEITY IN CHOROID PLEXUS CARCINOMA PATHOGENESIS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i34, https://doi.org/10.1093/neuonc/noad073.135
RARE-07. BONE MARROW ABLATIVE CHEMOTHERAPY ASSOCIATED WITH IMPROVED OUTCOMES AMONG PATIENTS WITH RELAPSED CENTRAL NERVOUS SYSTEM NON-GERMINOMATOUS GERM CELL TUMORS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i34–i35, https://doi.org/10.1093/neuonc/noad073.136
RARE-08. MULTI-INSTITUTIONAL ANALYSIS OF PEDIATRIC RELAPSED/REFRACTORY CENTRAL NERVOUS SYSTEM GERMINOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i35, https://doi.org/10.1093/neuonc/noad073.137
FINAL CATEGORY: HEALTH OUTCOMES (QOL, DEI, SURVIVORSHIP, NURSING, SOCIAL WORK)- OUTC
OUTC-01. ESTABLISHING THE PSYCHOMETRIC VALIDITY OF ATTENTIONAL MEASURES APPLIED TO THE PAEDIATRIC NEURO-ONCOLOGY POPULATION: A SYSTEMATIC REVIEW
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i35, https://doi.org/10.1093/neuonc/noad073.138
OUTC-02. CASE SERIES OF HYPERMUTATED PEDIATRIC CNS TUMORS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i35, https://doi.org/10.1093/neuonc/noad073.139
OUTC-03. IMPACT OF TREATMENT EXPOSURES AND SOCIOECONOMIC STATUS ON NEUROCOGNITIVE PERFORMANCE IN CHILDREN WITH BRAIN TUMORS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i35–i36, https://doi.org/10.1093/neuonc/noad073.140
OUTC-04. SUBSEQUENT CNS MALIGNANCY AMONG SURVIVORS OF CHILDHOOD CANCER: A REPORT FROM THE CHILDHOOD CANCER SURVIVOR STUDY (CCSS)
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i36, https://doi.org/10.1093/neuonc/noad073.141
OUTC-05. DIFFERENCES IN FACTORS INFLUENCING SURVIVAL IN CHILDHOOD AND ADULT CNS MALIGNANCIES
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i36, https://doi.org/10.1093/neuonc/noad073.142
OUTC-06. BEST PRACTICES FOR THE SUCCESSFUL ADMINISTRATION OF COMBINATION METRONOMIC ANTI-ANGIOGENIC AND INTRAVENTRICULAR THERAPY
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i36, https://doi.org/10.1093/neuonc/noad073.143
OUTC-07. ANALYZING PREDICTORS OF LOSS TO FOLLOW-UP AS SEEN AMONG YOUNG SURVIVORS OF CENTRAL NERVOUS SYSTEM TUMORS FOR QUALITY IMPROVEMENT INTERVENTIONS AT DANA FARBER CANCER INSTITUTE
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i36–i37, https://doi.org/10.1093/neuonc/noad073.144
OUTC-08. IMPLEMENTING SOCIAL DETERMINANT OF HEALTH DATA COLLECTION FOR PEDIATRIC, ADOLESCENT AND YOUNG ADULT NEURO-ONCOLOGY PATIENTS IN THE CLINICAL TRIAL CONSORTIA SETTING: PROGRESS AND CHALLENGES
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i37, https://doi.org/10.1093/neuonc/noad073.145
OUTC-09. PEDIATRIC LOW GRADE GLIOMA SURVIVORS’ NEED FOR SURVIVORSHIP CARE: ‘ENGAGE’ A MULTIDISCIPLINARY, E-HEALTH INTERVENTION
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i37, https://doi.org/10.1093/neuonc/noad073.146
OUTC-10. SELF-REPORTED RACE AND ETHNICITY AND GENETIC ANCESTRY GROUPS SHOW DISTINCT PREVALENCE AND OUTCOMES ACROSS PEDIATRIC CENTRAL NERVOUS SYSTEM TUMORS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i37, https://doi.org/10.1093/neuonc/noad073.147
OUTC-11. RACE AND AGE ARE ASSOCIATED WITH ICD-10 DIAGNOSES IN THE POST-OPERATIVE PERIOD FOR PEDIATRIC PATIENTS WITH PRIMARY BRAIN TUMORS UNDERGOING NEUROSURGERY
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i37–i38, https://doi.org/10.1093/neuonc/noad073.148
OUTC-12. BLACK IN CANCER: EMPOWERING AND ENCOURAGING FUTURE BLACK CANCER LEADERS WHILST REDUCING CANCER DISPARITIES THROUGH EDUCATION AND ADVOCACY
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i38, https://doi.org/10.1093/neuonc/noad073.149
FINAL CATEGORY: HIGH GRADE GLIOMA/GLIOMATOSIS CEREBRI - HGG
HGG-01. INFANT-TYPE HEMISPHERIC GLIOMA: NEW MOLECULAR ALTERATIONS AND PRECISION-MEDICINE TREATMENT
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i38, https://doi.org/10.1093/neuonc/noad073.150
